ArticleJournal for immunotherapy of cancer2026
IL4Rα blockade inhibits proliferation of malignant lymphocytes and the immunosuppressive tumor microenvironment of mycosis fungoides.
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited therapeutic options are available for patients with advanced-stage mycosis fungoides (MF), and the 5-year survival rate is 25%. Due to its critical role in MF pathogenesis, the IL4/IL13 pathway presents a promising target for treatment. Here, we analyzed blocking of IL4Rα, the common subunit of the IL4 and IL13 receptors, within the advanced-stage MF cutaneous tumor microenvironment (TME).
methodsCellular Indexing of Transcriptomes and Epitopes by sequencing was employed to assess the transcriptional profile of the cells expressing the IL4 and IL13 receptors within the advanced MF TME. We combined IL4Rα inhibition by REGN668 (dupilumab) in ex vivo skin explants from advanced MF patients with single-cell transcriptome and machine learning analysis to identify the molecular mechanisms of IL4Rα signaling within the MF skin lesions. Parallel analysis of the T cell immune repertoire allowed identification of the expanded malignant clone within each MF sample. Multicolor immunofluorescence microscopy was employed to validate molecular findings.
resultsREGN668 inhibits patient-specific processes in malignant lymphocytes; however, we also identified downregulation of common pathways among patient samples, including those associated with cell cycle progression, PI3K/AKT signaling, janus kinase (JAK)/Signal Transducer and Activator of Transcription (STAT) signaling, DNA damage/repair, and TP53 regulation. Furthermore, we showed that IL4Rα blockade in the TME of advanced MF downregulates multiple immunosuppressive pathways associated with myeloid-derived suppressor cells and LAMP3
conclusionsThese results provide new insights into advanced MF tumorigenesis and show that the effects of IL4Rα blockade are specific to the STAT6 pathway, inhibiting proliferation of malignant lymphocytes, as well as repressing several immunosuppressive mechanisms within the MF TME. However, the extensive genetic, transcriptional, and functional heterogeneity across MF patients indicates that inhibition of multiple driver pathways and a personalized therapeutic approach will be important for developing new therapeutic strategies against this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.